- Home
- ACRV vs ACCS Comparison
ACRV vs ACCS Comparison
Compare ACRV & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- ACCS
- Stock Information
- Founded
- ACRV 2018
- ACCS 1988
- Country
- ACRV United States
- ACCS United States
- Employees
- ACRV N/A
- ACCS N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- ACCS Publishing
- Sector
- ACRV Health Care
- ACCS Consumer Discretionary
- Exchange
- ACRV Nasdaq
- ACCS Nasdaq
- Market Cap
- ACRV 41.7M
- ACCS 46.2M
- IPO Year
- ACRV 2022
- ACCS N/A
- Fundamental
- Price
- ACRV $1.33
- ACCS $10.97
- Analyst Decision
- ACRV Buy
- ACCS Strong Buy
- Analyst Count
- ACRV 7
- ACCS 1
- Target Price
- ACRV $17.40
- ACCS $14.00
- AVG Volume (30 Days)
- ACRV 213.8K
- ACCS 15.1K
- Earning Date
- ACRV 08-13-2025
- ACCS 08-12-2025
- Dividend Yield
- ACRV N/A
- ACCS N/A
- EPS Growth
- ACRV N/A
- ACCS N/A
- EPS
- ACRV N/A
- ACCS N/A
- Revenue
- ACRV N/A
- ACCS $22,562,000.00
- Revenue This Year
- ACRV N/A
- ACCS $3.05
- Revenue Next Year
- ACRV $1,037.93
- ACCS $15.47
- P/E Ratio
- ACRV N/A
- ACCS N/A
- Revenue Growth
- ACRV N/A
- ACCS 26.44
- 52 Week Low
- ACRV $1.05
- ACCS $7.79
- 52 Week High
- ACRV $10.16
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- ACRV 51.00
- ACCS 40.79
- Support Level
- ACRV $1.27
- ACCS $10.82
- Resistance Level
- ACRV $1.42
- ACCS $11.38
- Average True Range (ATR)
- ACRV 0.08
- ACCS 0.69
- MACD
- ACRV 0.00
- ACCS -0.10
- Stochastic Oscillator
- ACRV 55.32
- ACCS 35.24
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.